Loading…
Loading…
The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.
Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health Incorporated (NYSE: ELAN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 51,700 shares of the company's stock, valued at approximately $1,272,000. Several other hedge funds and other institutional investors also
Corient Private Wealth LP purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE: ELAN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 348,043 shares of the company's stock, valued at approximately $8,565,000. Corient Private Wealth LP owned approximately
Corient Private Wealth LP raised its stake in Elanco Animal Health Incorporated (NYSE: ELAN) by 127.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 348,043 shares of the company's stock after acquiring an additional 195,312 shares during the
Algert Global LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 19.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 180,430 shares of the company's stock after selling 42,410 shares during the quarter. Algert Global LLC's holdings
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.
I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
The director upped their stake by 10,000 shares. This purchase increased the insider's direct equity holdings by 10%.